PMID:
Evid Based Complement Alternat Med. 2019 ;2019:9679234. Epub 2019 Apr 18. PMID: 31118973
Abstract Title:
for Diabetic Nephropathy: A Systematic Review and Meta-Analysis.
Abstract:
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD). Many trials have shown thatcould further improve proteinuria and protect kidney function in patients with DN when added to a renin-angiotensin system (RAS) blocker. A systematic assessment of the efficacy and safety ofin DN is essential. Eight electronic databases were searched to identify eligible trials published from inception to December 2017. The Cochrane Risk of Bias Tool was used to evaluate the methodological quality of eligible studies. Seventy-two studies with 5,895 participants were identified. The methodological quality of included studies was generally low. The results indicated that, compared to a RAS blocker, combined treatment ofwith a RAS blocker was more effective for 24h urinary protein (24h UP) (mean difference [MD], -0.39 [95% confidence interval [CI], -0.46 to -0.33] g/d; P
Health Time 